Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This appears to be a minor internal update with no impact on study details or user interactions.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedDifference0.3%

- Check54 days agoChange DetectedA new revision number v3.3.2 is shown, replacing the previous v3.2.0.SummaryDifference0.1%

- Check61 days agoChange DetectedThe NIH government operating status notice displayed on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedMinor formatting tweaks and small content updates on the study details page; the core study information and structure remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check104 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.